论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
杜皮单抗成功治疗慢性光化性皮炎:一病例报告和文献综述
Received 5 October 2021
Accepted for publication 16 November 2021
Published 30 December 2021 Volume 2021:14 Pages 1913—1917
DOI https://doi.org/10.2147/CCID.S342401
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Jeffrey Weinberg
Abstract: Chronic actinic dermatitis (CAD) is a rather rare photosensitive disease characterized by a persistent eczematous eruption in sun-exposed sites. The pathogenesis of CAD has not been completely elucidated. The clinical treatment of CAD is still challenging and not standardized. Some patients with severe CAD have achieved satisfactory clinical results with dupilumab when conventional therapies have failed. We herein report the case of a 45-year-old male with severe CAD who responded rapidly to combined treatment with dupilumab (600 mg for 1 week, and then 300 mg every 2 weeks) in 2 months. The patient experienced continuous improvement and no side effects from dupilumab (300 mg every month), having ceased other systemic medications. Dupilumab could be considered as an alternative or adjunctive treatment for CAD.
Keywords: chronic actinic dermatitis, dupilumab, treatment